Independent fund research. Built on SEC filings.

How we research funds

ETF · Large Blend · Simplify Exchange Traded

Simplify Propel Opportunities ETF (SURI)

Ticker SURI · Since 2023-03-27 · · Holdings as of Jun 30, 2026

Expense ratio
2.59%$259/yr per $10k
1-yr return
+25.1%as of Dec 2025
Net assets
$77.3Mall share classes
Holdings
39

Bottom line

Is SURI a good fund? The bottom line

SURI is an actively managed large blend ETF from Simplify Exchange Traded.

Annual fees run 2.59% — about $259 a year on every $10,000 invested, more expensive than 97% of large blend funds we track.

It returned +25.1% over one year (as of Dec 31, 2025, per its prospectus).

With $77.3 million in net assets and 39 holdings, its largest position is United States Of America - Bureau Of The Public Debt (76.8%) and the top 10 make up 155.1% of the portfolio.

What to watch

  • Expensive for its category (2.59%)
  • Concentrated: top 10 holdings are 155.1% of assets

Updated Nov 19, 2026

What SURI invests in

Investment Objective: The Simplify Propel Opportunities ETF (the Fund or SURI) seeks long-term capital appreciation.

Principal Investment Strategies: The Fund is an actively managed exchange-traded fund (ETF). The Funds investment adviser Simplify Asset Management Inc. (the Adviser) collaborates with the Funds sub-adviser, Propel Bio Management, LLC (the Sub-Adviser), to seek to achieve the Funds investment objective. The Fund concentrates its investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. Each of these industries are commonly categorized within the healthcare sector because they share similar economic features and regulatory constraints. The Fund also may invest in securities of issuers engaged in energy-related endeavors such as the production, generation, and sale of energy resources. The Sub-Adviser employs an actively managed opportunistic…

From the fund's prospectus (filed Oct 28, 2026).

SURI performance

Fund calendar-year total returns, 2024–2025 2024: −10.2%; 2025: +25.1% −10.2% 2024 +25.1% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
SURI+25.1%——
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full SURI performance history →

What SURI costs

On a $10,000 investment, SURI's 2.59% expense ratio costs about $259 a year. The prospectus estimates $3,152 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full SURI fee table →

SURI top 10 holdings

#Holding% of fund
1United States Of America - Bureau Of The Public Debt76.77%
2Plains Gp Holdings Lp PAGP39.97%
3Achieve Life Sciences Inc ACHV12.11%
4Milestone Pharmaceuticals Inc MIST5.81%
5Achieve Life Sciences Inc4.42%
6Delcath Systems Inc DCTH4.26%
7Phathom Pharmaceuticals Inc PHAT3.50%
8Corcept Therapeutics Inc CORT2.98%
9Abeona Therapeutics Inc ABEO2.76%
10Celldex Therapeutics Inc CLDX2.56%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 155.1% of the fund. See all top 25 holdings and asset mix →

Alternatives to SURI

More funds like SURI →

SURI FAQ

What is the expense ratio of SURI?
SURI's expense ratio is 2.59%, which works out to about $259 a year for every $10,000 invested. The prospectus estimates total costs of $3,152 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is SURI a good investment?
It depends on your goals, but the data points to: expensive for its category (2.59%); concentrated: top 10 holdings are 155.1% of assets. This is general information, not personalized advice.
What does SURI hold?
SURI's largest holdings are United States Of America - Bureau Of The Public Debt (76.8%), Plains Gp Holdings Lp (40.0%), Achieve Life Sciences Inc (12.1%), Milestone Pharmaceuticals Inc (5.8%), Achieve Life Sciences Inc (4.4%). It holds 39 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
Who manages SURI?
SURI is offered by Simplify Exchange Traded through Simplify Exchange Traded Funds.